This document summarizes a clinical study that evaluated the effectiveness of tranexamic acid (TA) plus sunscreen for treating melasma. The study involved 561 female patients with moderate or severe melasma who were randomly assigned to receive either 250 mg of oral TA twice daily plus sunscreen or placebo plus sunscreen. The primary outcome was improvement in melasma severity scores after 3 and 6 months. Results showed significantly greater improvement in melasma severity in the TA group compared to placebo at both timepoints. Common side effects of TA included headaches, nausea, and back pain. The study concluded that TA is effective and safe for treating moderate to severe melasma.
Text Snippets to Corroborate Medical Relations: An Unsupervised Approach usin...Maulik Kamdar
Knowledge graphs have been shown to significantly improve search results. Usually populated by subject matter experts, relations therein need to keep up to date with medical literature in order for search to remain relevant. Dynamically identifying text snippets in literature that confirm or deny knowledge graph triples is increasingly becoming the differentiator between trusted and untrusted medical decision support systems. This work describes our approach to mapping triples to medical text. A medical knowledge graph is used as a source of triples that are used to find matching sentences in reference text. Our unsupervised approach uses phrase embeddings and cosine similarity measures, and boosts candidate text snippets when certain key concepts exist. Using this approach, we can accurately map semantic relations within the medical knowledge graph to text snippets with a precision of 61.4% and recall of 86.3%. This method will be used to develop a novel application in the future to retrieve medical relations and corroborating snippets from medical text given a user query.
Objective: The objective of this study was to systematically review and conduct a direct and network meta-analysis of randomized controlled trials that have examined the clinical safety and efficacy of using passive and active immunotherapies in Alzheimer’s disease (AD).
(PDF) Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: A systematic review and network meta-analysis. Available from: https://www.researchgate.net/publication/331985667_Safety_and_efficacy_of_active_and_passive_immunotherapy_in_mild-to-moderate_Alzheimer's_disease_A_systematic_review_and_network_meta-analysis [accessed May 09 2020].
Text Snippets to Corroborate Medical Relations: An Unsupervised Approach usin...Maulik Kamdar
Knowledge graphs have been shown to significantly improve search results. Usually populated by subject matter experts, relations therein need to keep up to date with medical literature in order for search to remain relevant. Dynamically identifying text snippets in literature that confirm or deny knowledge graph triples is increasingly becoming the differentiator between trusted and untrusted medical decision support systems. This work describes our approach to mapping triples to medical text. A medical knowledge graph is used as a source of triples that are used to find matching sentences in reference text. Our unsupervised approach uses phrase embeddings and cosine similarity measures, and boosts candidate text snippets when certain key concepts exist. Using this approach, we can accurately map semantic relations within the medical knowledge graph to text snippets with a precision of 61.4% and recall of 86.3%. This method will be used to develop a novel application in the future to retrieve medical relations and corroborating snippets from medical text given a user query.
Objective: The objective of this study was to systematically review and conduct a direct and network meta-analysis of randomized controlled trials that have examined the clinical safety and efficacy of using passive and active immunotherapies in Alzheimer’s disease (AD).
(PDF) Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer’s disease: A systematic review and network meta-analysis. Available from: https://www.researchgate.net/publication/331985667_Safety_and_efficacy_of_active_and_passive_immunotherapy_in_mild-to-moderate_Alzheimer's_disease_A_systematic_review_and_network_meta-analysis [accessed May 09 2020].
Quality Lowers Cost: The Cost Effectiveness of a Multicenter Treatment Bundle for Severe Sepsis and Septic Shock By: Lydia Dong MD, MS; Intermountain Healthcare - Intensive Medicine Clinical Programs
Presented at the 11th Annual HSR/ PCOR Conference: Partnering for Better Health: Bringing Utah's Patient Voices to Research 2016
Aim: to evaluate the effi cacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma.
Methods: this was a retrospective observational clinical study. Patients were included in the study if they had >18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for treatment with ET.
Hyperthermia was performed with short radiofrequency waves of 13.56 MHz using a capacitive coupling technique keeping the skin surface at 26 C°. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumors was above 40 C° for more than 90% of the treatment duration (20-60 minutes gradually).
Lutein and Zeaxanthin Supplementation and Association With Visual Function in Age-Related Macular Degeneration
Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):252-8. doi: 10.1167/iovs.14-15553.
2013 impact factor for Investigative Ophthalmology & Visual Science: 3.661
Base Primary Prevention Decision ModelCTSI at UCSF
Presented by Stephanie Earnshaw, MD, MPH, at UCSF's symposium "The Role of Risk Stratification and Biomarkers in Prevention of Cardiovascular Disease" in Jan 2012.
Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (...Carevive
NOT FOR CME - FOR REFERENCE ONLY
In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016).
Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016).
Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.
Quality Lowers Cost: The Cost Effectiveness of a Multicenter Treatment Bundle for Severe Sepsis and Septic Shock By: Lydia Dong MD, MS; Intermountain Healthcare - Intensive Medicine Clinical Programs
Presented at the 11th Annual HSR/ PCOR Conference: Partnering for Better Health: Bringing Utah's Patient Voices to Research 2016
Aim: to evaluate the effi cacy and tolerability of electro-hyperthermia (ET) for the treatment of relapsed malignant glioma.
Methods: this was a retrospective observational clinical study. Patients were included in the study if they had >18 years, informed consent signed, histological diagnosis of malignant glioma, failure of previous temozolamide-based chemotherapy and radiotherapy, indication for treatment with ET.
Hyperthermia was performed with short radiofrequency waves of 13.56 MHz using a capacitive coupling technique keeping the skin surface at 26 C°. The applied power ranged between 40-150 Watts and the calculated average equivalent temperature in the tumors was above 40 C° for more than 90% of the treatment duration (20-60 minutes gradually).
Lutein and Zeaxanthin Supplementation and Association With Visual Function in Age-Related Macular Degeneration
Invest Ophthalmol Vis Sci. 2014 Dec 16;56(1):252-8. doi: 10.1167/iovs.14-15553.
2013 impact factor for Investigative Ophthalmology & Visual Science: 3.661
Base Primary Prevention Decision ModelCTSI at UCSF
Presented by Stephanie Earnshaw, MD, MPH, at UCSF's symposium "The Role of Risk Stratification and Biomarkers in Prevention of Cardiovascular Disease" in Jan 2012.
Improving Management of Non-Metastatic Castration-Resistant Prostate Cancer (...Carevive
NOT FOR CME - FOR REFERENCE ONLY
In 2018, there will be an estimated 164,690 new cases of prostate cancer (PC) in the U.S. and approximately 29,430 patients will die of the disease, making it the third-leading cause of cancer death in men (American Cancer Society [ACS], 2018). The majority of men with PC are treated with curative intent (i.e., with radical prostatectomy or radiation therapy) with good outcomes, but a fraction of men with locoregional PC will develop progressive disease. Men who have initial PSA/biochemical recurrence after curative treatment are a heterogeneous group of individuals with good overall prognosis, including a median metastasis-free survival (MFS) >8 years and a median overall survival (OS) of >23 years (Rozet et al., 2016).
Approximately 10%-20% of prostate cancer patients develop castration-resistant PC (CRPC) within approximately 5 years of follow-up. Decisions about clinical management (i.e., when to start treatment) are challenging because it is unclear which patients will have shorter versus longer survival, and metastatic disease is not always reliably detected with imaging (Rozet et al., 2016).
Multiple new targeted agents, including immunotherapy, second-generation hormone therapy, and androgen biosynthesis inhibitors have been recently approved. Two recently published studies (PROSPER and SPARTAN) have changed the standard of care for patients with nmCRPC.
Austin Ophthalmology is an open access, peer reviewed, scholarly journal dedicated to publish articles covering all areas of Ophthalmology.
The journal aims to promote latest information and provide a forum for doctors, researchers, physicians, and healthcare professionals to find most recent advances in the areas of Ophthalmology. Austin Ophthalmology accepts research articles, reviews, mini reviews, case reports and rapid communication covering all aspects of Ophthalmology.
Austin Ophthalmology strongly supports the scientific up gradation and fortification in related scientific research community by enhancing access to peer reviewed scientific literary works. Austin Publishing Group also brings universally peer reviewed journals under one roof thereby promoting knowledge sharing.
The Magnitude of Benefit from Adding Taxanes to Anthracyclines in the Adjuvan...Osama Elzaafarany, MD.
This presentation aims at providing the oncologists with a well-organized, inclusive and updated evidence of the benefit of adding taxanes in the adjuvant settings of breast cancer. It will answer some questions like, what are the indications of adding taxanes for those patients, and which regimen is best to chose.
It is directed mainly to clinical Oncologists, Medical Oncologists, Oncology residents and medical students who are interested in breast cancere.
Suitability & Capability of Pharmaceutical Measurement SystemsAjaz Hussain
The 21st century ushered in the Experience Economy in which Assurance is a critical patient experience that links directly to safety and efficacy of pharmaceuticals. To the only state that Assurance, in and of itself, is critical to quality, safety and efficacy would fail to emphasize its importance. Reduction of errors and external failures (e.g., Product Withdrawals, Recalls, Warning Letters, and Import Alerts) is an urgent need, and it is the need to ensure effective corrective actions and preventive actions and to improve continually. Continuous Improvement means reducing variability in a process. One can only improve a (manufacturing) process that is stable, capable and in a state of (statistical) control. In the pharmaceutical sector, we often talk about continual improvement, but we cannot objectively achieve it for many reasons that span from how we set specifications, use compendial standards, and how we “validated” our measurement systems and “control” manufacturing processes. The goals and aspirations of the FDA initiatives of Process Analytical Technology and Pharmaceutical CGMP’s for the 21st Century should have been realized with the accumulated guidance under ICH and the FDA Guidance on Process Validation (2011). This talk will discuss what it will take to realize these goals and to practice continuous improvement indeed.
Miami Breast Cancer Conference: Opioid-Sparing ERAS in Breast Surgery K Rojas MDKristinRojas1
Presenting the #MaimoBreastTeam Opioid-Sparing Breast Surgery ERAS Protocols: Surgeons have the opportunity to make a massive impact in the opioid crisis by minimizing superfluous opioid prescribing after surgery. Shown here are the practical aspects of opioid-minimization so you can bring these lumpectomy and mastectomy protocols to your own institution.
NGS-based diagnostic testing compared to single-marker genetic testing (SMGT), has the potential to improve testing efficiency and to identify more cancer patients who could benefit from targeted therapies, but the impact on outcomes and total costs of care is uncertain. Recent studies using simulation modeling informed with data from the Flatiron Health database, representing curated electronic health record-derived clinical information from 191 oncology practices, has shown only moderate cost effectiveness of NGS vs. SGMT for patients with advanced non-small cell lung cancer (aNSCLC). The data suggests, however, that efforts to increase the proportion of patients who receive targeted therapies would improve the cost-effectiveness of NGS. To effectively inform access and reimbursement policy decisions there is a need to examine the NGS value proposition from the perspective of all stakeholders.
Author(s) and affiliation(s): Lotte Steuten (Office of Health Economics, London, UK); Bernardo Goulart (Fred Hutchinson Cancer Research Center, Seattle, WA, US & Seattle Cancer Care Alliance, Seattle, WA, US); Neal J. Meropol (Flatiron Health, New York, NY, US & Case Western Reserve University, Cleveland, OH, US); Daryl Pritchard (Personalized Medicine Coalition, Washington, DC, US); and Scott D. Ramsey (Fred Hutchinson Cancer Research Center, Seattle, WA, US)
Event: ISPOR 2019
Location: New Orleans, LA, United States
Date: 20/05/2019
Optimizing Therapeutic Strategies in Castration-Resistant Prostate Canceri3 Health
This activity will discuss emerging efficacy and safety data on novel therapies for nmCRPC and mCRPC, strategies to manage adverse events, and the role of imaging studies and PSA testing in evaluating treatment response.
Focusing on Pharmacist-Led Programs to Improve Medication Management Produces...Heidi Yanoski
This MBA Thesis presentation looks at pharmacist-led programs that not only improve patient outcomes, but help save millions by preventing medication errors, thirty-day hospital readmissions, and medication-induced morbidity and mortality.
Clinical and Commercial Experience With CoolSculpting (Aesthetic Journal of S...Laura Pietrzak
Article published in the Aesthetic Journal of Surgery title, "Clinical and Commercial Experience With CoolSculpting". Features work by Laura Pietrzak using the CoolSculpting device.
Cancer in the workplace is an Economist Intelligence Unit (EIU) report, sponsored by Bristol-Myers Squibb. It assesses the challenges that cancer poses for employers, examines workplace policies and practices to address the needs of those affected by the disease, and explores possible measures to strengthen workplace support.
In August-September 2016 The EIU surveyed 500 executives—150 from Europe, the Middle East and Africa (EMEA), 150 from the Americas, 150 from Asia-Pacific and 50 from the rest of the world—on their companies’ approaches to cancer in the workplace. Survey respondents were drawn from a variety of sectors and functions (see Appendix). This report is based on the results of the survey. The EIU also conducted ten in-depth interviews with experts on cancer in the workplace. The insights from these interviews appear throughout the report. We would like to thank the following individuals (listed alphabetically) for sharing their insight and experience:
You are an employee at Novartis. The company is currently addres.docxodiliagilby
You are an employee at Novartis. The company is currently addressing potential exclusions from formulary due to the introductions of generic versions as well as the introduction of other branded competitors. The company would like to develop a budget impact analysis and understand the budget impact in the treatment of Newly diagnosed adult with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase for both the Commercial and Medicare populations. You are tasked with developing this analysis as an economic model and providing your senior management with the budget impact and per member per month (PMPM) impact for both payer types.
Additional key question to answer: What is the discount needed to stay cost neutral with generic versions as well other branded products that fall within the same therapeutic class (tyrosine kinase inhibitors) of the market uptake that must occur such that the budget impact to payers exceeds $0.05 PMPM at 3 years?
DMS:Dasatinib
Dosing: One pill, once daily, either in the morning or in the evening
Dosing is the same for both newly diagnosed and imatinib-resistant or -intolerant CP Ph+ CML patients. For patients taking Dasatinib 100 mg daily, a dose decrease to 20 mg should be considered.
Novartis: : Tasigna® (nilotinib)
Dosing:300 mg
TASIGNA® (nilotinib) capsules doses should be taken approximately 12 hours apart. Adult patients should take 2 capsules in the morning and 2 capsules in the evening Capsules should be swallowed whole with water Patients must avoid food for 2 hours before and 1 hour after each dose For patients who cannot swallow TASIGNA capsules whole, the contents of each capsule may be sprinkled in 1 teaspoon of applesauce (puréed apple). The mixture should be swallowed right away (within 15 minutes) and should not be stored for future use
indicated population
Comparators--Dasatinib
Model feature DescriptionNotes Perspective and audiencepayers NovartisPopulation Commercial and MedicareIndication The worldwide annual incidence of CML is approximately 1–1.5 in 100,000 persons.In United State, 8990 people were diagnosed with CML in 2019.Time horizon5 yearsCost $16470/50mgThe cost for Tasigna oral capsule 50 mg is around $16,470 for a supply of 120 capsules, depending on the pharmacy you visit
Drug brand/genericDose frequencystrengthDoses per administration/yearAverage Wholesale Price (AWP)
Nilotinib(Tasigna)brandDaily 400mg2/365$196,473Dasatinib(Sprycel)brandDaily 100mg1/365$185,932Imatinib(Gleevec)brandDaily 400mg2/365$145,764Bosutinib(Bosulif)brandDaily 500mg1/365$204,706Ponatinib(Iclusig)brandDaily 45mg1/365$238,478
Comparators
Feature Product of NovartisProduct of DMSBenefit designMedicalMedicalPatient cost-sharingCo-insurance(initial coverage phase:25% to 33%-coverage gap phase: 45%-50% coinsurance)Co-pay (driven from 4171 to 16684)
Mode of administrationOrally twice dailyOral once dailyDuration of treatmentChronic(18.4 months)Chronic(15 months ...
Similar to Journal reading: Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma (20)
This is a lecture from a series of an acupuncture training course held in Mysuru, India.
<About the Course>
'Arouse the life zeal within you' through acupuncture, to heal head to toe without drugs. This training will focus on the TCM theories, its applications, diagnosis & cupping techniques. As the premier event, we have unique opportunity of having the experts of acupuncture from Taiwan as resource trainers.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ABDOMINAL TRAUMA in pediatrics part one.drhasanrajab
Abdominal trauma in pediatrics refers to injuries or damage to the abdominal organs in children. It can occur due to various causes such as falls, motor vehicle accidents, sports-related injuries, and physical abuse. Children are more vulnerable to abdominal trauma due to their unique anatomical and physiological characteristics. Signs and symptoms include abdominal pain, tenderness, distension, vomiting, and signs of shock. Diagnosis involves physical examination, imaging studies, and laboratory tests. Management depends on the severity and may involve conservative treatment or surgical intervention. Prevention is crucial in reducing the incidence of abdominal trauma in children.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMSAkankshaAshtankar
MIP 201T & MPH 202T
ADVANCED BIOPHARMACEUTICS & PHARMACOKINETICS : UNIT 5
APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS By - AKANKSHA ASHTANKAR
6. From: Interpretability of the Modified Melasma Area and Severity Index (mMASI)
JAMA Dermatol. 2016;152(9):1051-1052. doi:10.1001/jamadermatol.2016.1006
Determination of the Modified MASI (mMASI) Score